rs784504

This variant is located in the CSRNP1 gene.

GWAS Catalog Trait Associations (6)

Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.

glomerular filtration rate

Allele C
OR 7.24
p 4.0e-13
N 1,508,659
Large GWAS
multi-ancestry

free cholesterol in small HDL measurement

Zoodsma M et al. A genetic map of human metabolism across the allele frequency spectrum. Nature Genetics 57(10):2445-2455 (2025)
Allele C
OR 0.02
p 5.0e-12
N 450,015
Large GWAS
multi-ancestry

level of protein S100-G in blood

Allele C
OR 0.05
p 7.0e-12
N 47,745
Large GWAS
European

glutamine measurement

Zoodsma M et al. A genetic map of human metabolism across the allele frequency spectrum. Nature Genetics 57(10):2445-2455 (2025)
Allele C
OR 0.02
p 2.0e-11
N 450,015
Large GWAS
multi-ancestry

total lipids in small HDL measurement

Zoodsma M et al. A genetic map of human metabolism across the allele frequency spectrum. Nature Genetics 57(10):2445-2455 (2025)
Allele C
OR 0.02
p 1.0e-10
N 450,015
Large GWAS
multi-ancestry

sex hormone-binding globulin measurement

Allele C
OR 0.02
p 2.0e-9
N 196,901
Large GWAS
European
Allele C
OR 0.01
p 2.0e-8
N 189,473
Large GWAS
European

About CSRNP1

This gene encodes a protein that localizes to the nucleus and expression of this gene is induced in response to elevated levels of axin. The Wnt signalling pathway, which is negatively regulated by axin, is important in axis formation in early development and impaired regulation of this signalling pathway is often involved in tumors. A decreased level of expression of this gene in tumors compared to the level of expression in their corresponding normal tissues suggests that this gene product has a tumor suppressor function. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2016]

View all CSRNP1 variants →

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…